38 results about "Flunarizine Hydrochloride" patented technology

The present invention provides a flunarizine hydrochloride bulk injection and its production process. Its preparation range, every ampule contains 2mg-50mg of flunarizine hydrochloride and 0.1 ml-10 ml of 1.2-propylene glycol, the solvent respectively can be glucose, sodium chloride and glucose sodium chloride, and their contents respectively are 1g-50g of glucose and 0.3g-10g of sodium chloride. Its production process includes the following steps: placing 20ml of 1.2-propylene glycol in a container, then adding flunarizine hydrochloride, in said container, heating, stirring and dissolving; using injection water to dissolve glucose, stirring, adding it into container, diluting and dissolving, adding injection water to full dose, adding active carbon, heating to 80-90 deg.C, heat-insulating for 15 min., filtering and removing carbon, secondary filtering, adding flurnarizine hydrochloride and 1.2-propylene glycol mixed liquor, stirring them uniformly, regulating pH to 3.5-5.0 so as to obtain the invented product.

The invention relates to compound flunarizine hydrochloride and a preparation process thereof. The compound flunarizine hydrochloride is prepared from the following raw materials in part by weight: 0.7 part of flunarizine hydrochloride, 25 parts of root of red-rooted salvia, 20 parts of common burreed rhizome, 18 parts of zedoary, 15 parts of tall gastrodia tuber and 10 parts of glossy privet fruit, starch live edible cellulose serving as a pharmaceutic adjuvant are added according to the conventional pharmaceutic method to prepare formulations such as capsules, tablets, granules and the like. The compound flunarizine hydrochloride medicinal composition addresses both root causes and symptoms on epilepsy, is non-toxic and harmless to human bodies, does not have side effect, is low in cost and easy and convenient to prepare, and has a bright application prospect.

The invention discloses a method for detecting related substances in flunarizine hydrochloride preparations. The test solution, control solution and impurity mixed solution are respectively taken for high-performance liquid chromatography detection, and each substance in the test product is detected at 210nm and 253nm respectively. Impurity content; where impurity A and 4,4-difluorobenzyl alcohol peaks were detected at 210nm, and the impurity content was calculated by the external standard method; other impurity peaks were detected at 253nm, and the impurity content was calculated by the self-control method. The method of the invention is easy to operate, has short analysis time, strong specificity and high sensitivity, and can effectively separate 7 impurities, including 2 process impurities and 5 degraded impurities. The separation between impurities and adjacent peaks can reach above 1.5.

The invention relates to a pharmaceutical composition of ticagrelor and a type II therapeutic agent and a preparation method of the pharmaceutical composition. The pharmaceutical composition is characterized in that the type II therapeutic agent is selected from one or more of troxerutin, cinnarizine, flunarizine hydrochloride, ligustrazine, ligustrazine phosphate, sodium ferulate or piperazine ferulate. The invention also relates to application of the pharmaceutical composition in drugs, in particular the application in inhibiting or reversing of atherosclerosis lipid plaques of artery blood vessel.

Flunarizine hydrochloride matrix sustained-release tablets are prepared from, by weight, 25-55 parts of flunarizine hydrochloride, 35-55 parts of a matrix material, 5-10 parts of diluent, 3-5 parts of a binding agent and 2-5 parts of a lubricating agent. A preparing method of the flunarizine hydrochloride matrix sustained-release tablets comprises the following steps that flunarizine hydrochloride, the matrix material, the diluent the lubricating agent and the binding agent are mixed evenly and them directly pressed into the tablets in a powder mode or flunarizine hydrochloride, the matrix material, the diluent and the binding agent are mixed to be prepared into granules, the granules are then mixed with the lubricating agent evenly, and the tablets are obtained through tabletting. The flunarizine hydrochloride matrix sustained-release tablets overcome the defect that in the prior art, multiple times of administration needs to be conducted due to the short relative half-life period of flunarizine hydrochloride, and it can be avoided that to maintain the blood concentration with the effective amount to reach a treatment effect, initial over-doses in the initial administration period occur, and consequently many side effects are caused; the problem that due to insufficient doses, the pain of a patient cannot be relieved, and the treatment effect cannot be achieved is also solved.

The invention discloses a film agent quickly dissolved in the oral cavity and a preparation method thereof. The film agent consists of the following components in percentage by weight: 0.1 to 70 percent of medicinal active ingredients, 30 to 90 percent of water-soluble film forming material, 2 to 20 percent of plasticizer, 0 to 5 percent of disintegrating agent, and 1 to 20 percent of water, wherein the medicinal active ingredients are selected from modified or non-modified cobra venom, sumatriptan succinate, ergotamine dihydrogen tartrate and lomerizine hydrochloride or flunarizine hydrochloride. The film agent is quick in response, and avoids decomposition in gastrointestinal tracts due to oral administration to reduce the treatment effect. The preparation method is simple, economic and practical, and facilitates industrialized batch production.

The invention discloses a detection method for the dissolution determination of flunarizine hydrochloride capsules. The method is as follows: the dissolution method is the paddle method, 100 revolutions per minute, and the medium with sodium lauryl sulfate is added as the dissolution medium; high-efficiency liquid phase Chromatographic detection of dissolved matter, with octadecylsilane bonded silica gel as filler; UV detector, detection wavelength is 251-255nm; column temperature is 25-45°C; flow rate is 0.9-1.1ml / min; mobile phase is Methanol and Phosphate Buffers. The method of the invention solves the adsorption problem of the flunarizine hydrochloride capsule filter membrane, and the obtained chromatographic peak shape is good, the column efficiency is high, the obtained result can be made more accurate, the service life of the chromatographic column is prolonged, and the test cost is reduced .

The invention relates to a flunarizine-hydrochloride pharmaceutical composition and a preparing method thereof, and belongs to the technical field of medicine making. The flunarizine-hydrochloride pharmaceutical composition in the technical scheme is characterized in that every one thousand compositions comprise 5.9 g of flunarizine hydrochloride, 62.5 g-82.5 g of lactose, 70 g-90 g of microcrystalline cellulose, 3.2-12.8 g of sodium carboxymethylcellulose, 0.8 g of silicon dioxide, 0.8 g of magnesium stearate and 1-1.6 g of docusate sodium. According to the flunarizine-hydrochloride pharmaceutical composition and the preparing method thereof, a tablet with the small resolving degree RSD is provided through reasonable compatibility, the prepared tablet is stable in long-term storage, and high-quality medicine is provided for a clinic.